Effect of chlorzoxazone in patients with downbeat nystagmus: A pilot trial

Neurology

Volumn 81, Issue 13, 2013, Pages 1152-1158

  Feil, Katharina ^a   Claaßen, Jens ^a   Bardins, Stanislavs ^a   Teufel, Julian ^a   Krafczyk, Siegbert ^a   Schneider, Erich ^a   Schniepp, Roman ^a   Jahn, Klaus ^a   Kalla, Roger ^a   Strupp, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CENTRAL MUSCLE RELAXANT;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BODY EQUILIBRIUM; CLINICAL ARTICLE; DISEASE DURATION; DIZZINESS; DRUG EFFECT; EYE MOVEMENT; FEMALE; HUMAN; LONG TERM CARE; MALE; NYSTAGMUS; OBSERVATIONAL STUDY; ONSET AGE; PILOT STUDY; PRIORITY JOURNAL; STABILOGRAPHY; CHI SQUARE DISTRIBUTION; FOLLOW UP; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; CHI-SQUARE DISTRIBUTION; CHLORZOXAZONE; EYE MOVEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; NYSTAGMUS, PATHOLOGIC; PILOT PROJECTS; POSTURAL BALANCE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84884620972     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a55f6d     Document Type: Article

References (19)

1. Kalla R, Glasauer S, Buttner U, Brandt T, Strupp M. 4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 2007; 130:2441-2451. (Pubitemid 47327634)
2. Kalla R, Glasauer S, Schautzer F, et al. 4-Aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology 2004;62:1228-1229. (Pubitemid 38456530)
3. Wagner JN, Glaser M, Brandt T, Strupp M. Downbeat nystagmus: Aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry 2008;79:672-677. (Pubitemid 351829440)
4. Kalla R, Deutschlander A, Hufner K, et al. Detection of floccular hypometabolism in downbeat nystagmus by fMRI. Neurology 2006;66:281-283. (Pubitemid 43970177)
5. Strupp M, Thurtell MJ, Shaikh AG, Brandt T, Zee DS, Leigh RJ. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol 2011;258:1207- 1222.
6. Alvina K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 2010; 30:7258-7268.
7. Alvina K, Khodakhah K. KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci 2010;30: 7249-7257.
8. Gao Z, Todorov B, Barrett CF, et al. Cerebellar ataxia by enhanced Ca(V)2.1 currents is alleviated by Ca21-dependent K1-channel activators in Cacna1a(S218L) mutant mice. J Neurosci 2012;32:15533-15546.
9. Cao Y, Dreixler JC, Roizen JD, Roberts MT, Houamed KM. Modulation of recombinant small-conductance Ca(21)- Activated K(1) channels by the muscle relaxant chlorzoxazone and structurally related compounds. J Pharmacol Exp Ther 2001;296:683-689. (Pubitemid 32187335)
10. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage 2004;28:140-175. (Pubitemid 38970077)
11. Bachmann K, Sarver JG. Chlorzoxazone as a single sample probe of hepatic CYP2E1 activity in humans. Pharmacology 1996;52:169-177. (Pubitemid 26076284)
12. Glasauer S, HoshiM, Kempermann U, Eggert T, Buttner U. Three-dimensional eye position and slow phase velocity in humans with downbeat nystagmus. J Neurophysiol 2003;89: 338-354. (Pubitemid 36134026)
13. Krafczyk S, Tietze S, Swoboda W, Valkovic P, Brandt T. Artificial neural network: A new diagnostic posturographic tool for disorders of stance. Clin Neurophysiol 2006;117: 1692-1698. (Pubitemid 44094258)
14. Cohen HS, Kimball KT. Development of the Vestibular Disorders Activities of Daily Living Scale. Arch Otolaryngol Head Neck Surg 2000;126:881-887. (Pubitemid 30460658)
15. Strupp M, Schuler O, Krafczyk S, et al. Treatment of downbeat nystagmus with 3, 4-diaminopyridine: A placebocontrolled study. Neurology 2003;61:165-170. (Pubitemid 36875295)
16. Syme CA, Gerlach AC, Singh AK, Devor DC. Pharmacological activation of cloned intermediate- And small-conductance Ca(21)-activated K(1) channels. Am J Physiol Cell Physiol 2000;278:C570-C581. (Pubitemid 30154937)
17. Kasumu AW, Hougaard C, Rode F, et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol 2012;19: 1340-1353.
18. Strupp M, Kalla R, Claassen J, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 2011;77:269-275.
19. Schniepp R, Wuehr M, Neuhaeusser M, et al. 4-Aminopyridine and cerebellar gait: A retrospective case series. J Neurol 2012;259:2491-2493.